| Literature DB >> 25814530 |
Rachelle G Veenstra1, Ryan Flynn1, Katharina Kreymborg2, Cameron McDonald-Hyman1, Asim Saha1, Patricia A Taylor1, Mark J Osborn1, Angela Panoskaltsis-Mortari1, Annette Schmitt-Graeff3, Elisabeth Lieberknecht4, William J Murphy5, Jonathan S Serody6, David H Munn7, Gordon J Freeman8, James P Allison9, Tak W Mak10, Marcel van den Brink2, Robert Zeiser4, Bruce R Blazar1.
Abstract
Members of the B7 family have been shown to be important for regulating immune responses by providing either positive or negative costimulatory signals. The function of B7-H3 has been controversial. We show that B7-H3 is upregulated in graft-versus-host disease (GVHD) target organs, including the colon, liver, and lung. Infusion of allogeneic donor T cells into B7-H3(-/-) vs wild-type (WT) recipients resulted in increased GVHD lethality associated with increased T-cell proliferation, colonic inflammatory cytokines, and destruction of epithelial barriers. Allogeneic B7-H3(-/-) vs WT donor T cells also had increased T-cell proliferation and GVHD lethality associated with increased proliferation and cytokine secretion in the spleen, intraepithelial lymphocyte inflammatory cytokines, and intestinal permeability. Both resting and activated regulatory T cells (Tregs) lack B7-H3 messenger RNA. Consistent with these data, GVHD was augmented in recipients of B7-H3(-/-) Treg-depleted grafts. In two delayed lymphocyte infusion (DLI) models, T cells lacking B7-H3 are capable of providing graft-versus-leukemia (GVL) effects. We conclude that B7-H3 is responsible for providing a negative costimulatory signal. Our studies provide support for developing and testing new therapies directed toward the B7-H3 pathway, including approaches to augment host B7-H3 early after bone marrow transplantation to prevent GVHD and to develop potent antagonistic antibodies later after transplant to facilitate DLI-mediated GVL without GVHD complications.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25814530 PMCID: PMC4440885 DOI: 10.1182/blood-2014-09-603357
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113